|Bid||20.77 x N/A|
|Ask||20.78 x N/A|
|Day's Range||20.55 - 20.94|
|52 Week Range||11.32 - 21.16|
|Beta (5Y Monthly)||0.56|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||0.24 (1.19%)|
|1y Target Est||11.39|
Whilst it may not be a huge deal, we thought it was good to see that the Fisher & Paykel Healthcare Corporation...
Increase in profitability and industry-beating performance can be essential considerations in a stock for some...
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
New Zealand medical device maker Fisher & Paykel Healthcare Corp Ltd and U.S. rival ResMed Inc have agreed to settle patent infringement disputes, ending a three-year tussle that spanned the globe and cost each side millions of dollars in legal fees. In a joint statement on Thursday, the companies agreed to end all ongoing infringement cases and said neither would admit liability or make any payment. Fisher & Paykel shares were 6.9 percent higher after the announcement, reaching a more than four-month peak, whereas ResMed's Australian depository receipts were 1.1 percent firmer.
Medical device maker Fisher & Paykel Healthcare and U.S.-based ResMed on Thursday agreed to settle disputes over patent infringement, bringing to an end a tussle spanning the globe. The two companies had ...
ResMed (NYSE: RMD, ASX: RMD), and Fisher & Paykel Healthcare (NZX: FPH, ASX: FPH) today announced an agreement to settle all outstanding patent infringement disputes between the companies in all venues around the world. The settlement involves no payment or admission of liability by either side. “I am pleased we were able to resolve these disputes,” said ResMed CEO Mick Farrell.